By Zinnia Jones
- Cyproterone acetate and meningioma risk in trans women (March 31, 2018)
- Update on case reports: Cyproterone acetate and meningioma in trans women (November 30, 2018)
- Lower doses of cyproterone acetate may be similarly effective for blocking testosterone, with a lower risk of adverse effects (August 31, 2020)
- Study of entire French population offers further data on cyproterone acetate and meningioma risk (February 28, 2021)
- Additional data confirms 10mg of cyproterone acetate (CPA) is effective for testosterone suppression in trans women (June 30, 2021)
- Denmark population-wide study confirms association between cyproterone acetate and meningioma risk – and recent users of CPA are disproportionately trans women (July 31, 2021)
Last updated: January 8, 2022
